NATIMAB
Desconocido
EDePDAC: Feasibility study for the validation and industrialization of two diagnostic kits in both ELISA and...
NATIMAB THERAPEUTICS SRL
tramitó un
H2020:
H2020-SMEInst-2014-2015
In this study we propose to investigate the feasibility of the industrial development and validation up to the CE marking of two immunodiagn...
2015-04-23 - 2015-10-31 | Financiado
2015-04-23 - 2015-10-31 | Financiado
EPC-TM-NET: Targeting the tumour microenvironment to improve pancreatic cancer prognosis
NATIMAB THERAPEUTICS SRL
participó en un
FP7:
Pancreatic cancer is one of the most lethal human cancers with a five-year survival rate of less than 5%. Late presentation and a high level...
Financiado
Financiado
* No se disponen de datos de la empresa actual.